A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant

International Journal of Pharmaceutics

Volumn 340, Issue 1-2, 2007, Pages 104-118

  Iyer, Sunil S ^a   Barr, William H ^a   Dance, Mario E ^a   Coleman, Peter R ^b   Karnes, H Thomas ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b The Coleman Institute   (United States)

Author keywords

Capillary and flow through devices; In vitro release testing; Modified Hanks' Balanced Salts Solution; Naltrexone implant

Indexed keywords

NALTREXONE; POLITEF; POLYCARBONATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOREACTOR; CELL CULTURE; CONTROLLED STUDY; DEVICE; DOSE TIME EFFECT RELATION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG IMPLANT; DRUG RELEASE; FILTER; FLOW RATE; HISTOLOGY; IMPLANTATION; KINETICS; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANIMALS; BIOREACTORS; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; DOGS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; EQUIPMENT DESIGN; FOREIGN-BODY REACTION; KINETICS; MODELS, BIOLOGICAL; NALTREXONE; NARCOTIC ANTAGONISTS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SUBCUTANEOUS TISSUE; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 34447251651     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.03.032     Document Type: Article

References (63)

1. Agrawal C.M., and Athanasiou K.A. Technique to control pH in vicinity of biodegrading PLA-PGA implants. J. Biomed. Mater. Res. 38 (1997) 105-114
2. Allababidi S., and Shah J.C. Kinetics and mechanism of release from glyceryl monostearate-based implants: evaluation of release in a gel simulating in vivo implantation. J. Pharm. Sci. 87 (1998) 738-744
3. Anderson J.M. In vivo biocompatibility of implantable delivery systems and biomaterials. Eur. J. Pharmacol. 40 (1994) 1-8
4. Athanasiou K.A., Niederauer G.G., and Agrawal C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17 (1996) 93-102
5. Ballard, B.E., 1961. The physicochemical properties of drugs that control their absorption rate after implantation. Ph.D. Thesis. University of California, San Francisco, USA.
6. ®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 28 (2003) 1973-1982
7. Benet L.Z. The effect of route of administration and distribution on drug action. In: Banker G.S., and Rhodes C.T. (Eds). Modern Pharmaceutics, 2nd ed. Drugs and the Pharm. Sci. Series vol. 40 (1990), Marcel Dekker Inc., New York 181-207
8. Bergsma J.E., Rozema F.R., Bos R.R.M., Boering G., De Bruijn W.C., and Pennings A.J. In vivo degradation and biocompatibility study of in vitro pre-degraded polymerized polylactide particles. Biomaterials 16 (1994) 267-274
9. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltexone implants can block very large amounts of heroin: a report of two cases. Addict. Biol. 7 (2002) 321-323
10. Burgess, D.J., Hussain, A.S., Ingallinera, T.S., Chen, M.L., 2002. Assuring Quality and Performance of Sustained and Controlled Release Parenterals: Workshop Report. AAPS Pharm. Sci., 4, article 7.
11. Chien Y.W. Methods to achieve sustained drug delivery. In: Robinson J.R. (Ed). Physical Approach: Implants, Sustained and Controlled Release Drug Delivery Systems (1978), Marcel Dekker Inc., New York 211-349
12. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., and Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159 (2002) 351
13. Cukierski M.J., Johnson P.A., and Beck J.C. Chronic (60-week) toxicity study of Duros leuprolide implants in dogs. Int. J. Toxicol. 20 (2001) 369-381
14. Davies P.F. How do vascular cells respond to flow?. NIPS 4 (1989) 22-25
15. Davis B.K. Diffusion in polymer gel implants. Proc. Natl. Acad. Sci. 71 (1974) 3120-3123
16. Dunne A., O'Hara T., and Devane J. Approaches to IVIVR modeling and statistical analysis. Adv. Exp. Med. Biol. 423 (1997) 67-86
17. Eckenhoff B., Theeuwes F., and Urquhart F. Osmotically actuated dosage forms for rate-controlled drug delivery. Pharm. Tech. 11 (1987) 96-105
18. Enevoldsen L.H., Simonsen L., Stallknecht B., Galbo H., and Bülow J. In vivo human lipolytic activity in preperitoneal and subdivisions of subcutaneous abdominal adipose tissue. Am. J. Physiol. Endocrinol. Metab. 285 (2001) E1110-E1114
19. FDA, 1997. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations.
20. Freed L.E., Langer R., Martin I., Pellis N.R., and Vunjak-Novakovic G. Tissue engineering of cartilage in space. Proc. Natl. Acad. Sci. 94 (1997) 13885-13890
21. Gao J., Szymanski A., Stowe N., and Haaga J. Monitoring drug release and distribution in vivo by computed tomography. BED, Bioengineering Conference. Am. Soc. Mech. Eng. (2001) 95-96
22. Goiss G., Parreira D.R., and Suzigan S. A study on the biocompatibility and integration of acellular polyanionic collagen:elastin matrices by soft tissue. Brazilian J. Biomed. Eng. 19 (2003) 167-173
23. Göpferich A. Polymer degradation and erosion: mechanisms and applications. Eur. J. Pharm. Biopharm. 42 (1996) 1-11
24. Hollingshead M.G., Alley M.C., Camalier R.F., Abbott B.J., Mayo J.G., Malspeis L., and Grever M.R. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57 (1995) 131-141
25. Huang X., and Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Rel. 73 (2001) 121-136
26. Hulse G.K., Arnold-Reed D.E., O'Neil G., Chan C.-T., Hansson R., and O'Neil P. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict. Biol. 9 (2004) 59-65
27. Hulse G.K., Stalenberg V., McCallum D., Smit W., O'Neil, Morris N., and Tait R.J. Histological changes over time around the site of sustained release naltrexone-poly(dl-lactide) implants in humans. J. Control. Rel. 108 (2005) 43-55
28. Iyer S.S., Barr W.H., and Karnes H.T. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm. Drug Dispos. 27 (2006) 157-170
29. Iyer S.S., Barr W.H., and Karnes H.T. Characterization of a potential medium for 'biorelevant' in vitro release testing of a naltrexone implant, employing a validated stability-indicating HPLC method. J. Pharm. Biomed. Anal. 43 (2007) 845-853
30. Iyer, S.S., Kellogg, G.E., Karnes, H.T., submitted for publication. A liquid chromatography-electrospray tandem mass spectrometry method for the analysis of naltrexone in canine plasma employing a molecular model to demonstrate the absence of internal standard deuterium isotope effects. J. Chromatogr. Sci.
31. Kalkwarf D.R., Sikov M.R., Smith L., and Gorden R. Release of progesterone from polyethylene devices in vitro and in experimental animals. Contraception 6 (1972) 423-431
32. Langer R., and Peppas N.A. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 49 (2003) 2990-3006
33. Lee M.C., Wagner Jr. H.N., Tanada S., Frost J.J., Bice A.N., and Dannals R.F. Duration of occupancy of opiate receptors by naltrexone. J. Nucl. Med. 29 (1988) 1207-1211
34. Li S.M., Garreau H., and Vert M. Structure-property relationships in the case of degradation of massive poly(α-hydroxy acids) in aqueous media. Part I. Poly(dl-lactic acid). J. Mater. Sci.: Mater. Med. 1 (1990) 123-130
35. Lickorish D., Chan J., Song J., and Davies J.E. An in vivo model to interrogate the transition from acute to chronic inflammation. Eur. Cells Mater. 8 (2004) 12-20
36. Miclau T., Dahners L.E., and Lindsey R.W. In vitro pharmacokinetics of antibiotic release from locally implantable materials. J. Orthopaed. Res. 11 (1993) 627-632
37. Mikac U., Demšar A., Serša I., and Demšar F. Electric density imaging of a tablet dissolution. Proc. Int. Conf. Life Sci. (2001) 11
38. Mohl, S., Reithmeier, H., Winter, G., 2002. Poster presentation: sustained release of BSA from implant systems by using physiological lipids. In: Proceedings of the Colorado Protein Stability Conference, Breckenbridge, CO, USA. Website: http://www.chemie.uni-muenchen.de/pb/aks/winter/Mohl_poster_denver_072002.pdf, October 17, 2003.
39. Narasimhan B., Snaar J.E.M., Bowtell R.W., Morgan S., Melia C.D., and Peppas N.A. Magnetic Resonance Imaging analysis of molecular mobility during dissolution of poly(vinyl alcohol) in water. Macromolecules 32 (1999) 704-710
40. National Aeronautics and Space Administration, 1995. NASA Technology Spinoffs: bringing space down to earth. FS-1995-08-004JSC.
41. Pappenheimer J.R., Renkin E.M., and Borrero L.M. Filtration, diffusion and molecular sieving through peripheral capillary membranes: A contribution to the Pore Theory of Capillary Permeability. Am. J. Physiol. 167 (1951) 13-46
42. Perez-Reyes M., and Wall M.E. A comparative study of the oral, intravenous, and subcutaneous administration of 3H-naltrexone to normal male volunteers. NIDA Res. Monogr. 28 (1981) 93-101
43. Pitt C. Poly-ε-caprolactone and its copolymers. In: Chasin M., and Langer R. (Eds). Biodegradable Polymers as Drug Delivery Systems, Drugs and the Pharm. Sci. Series vol. 45 (1990), Marcel Dekker Inc., New York 71-120
44. Polli J.E., Crison J.R., and Amidon G.L. Novel approach to the analysis of in vitro-in vivo relationships. J. Pharm. Sci. 85 (1996) 753-760
45. Redmond E.M., Cahill P.A., and Sitzmann J.V. Perfused transcapillary smooth muscle and endothelial cell co-culture-a novel in vitro model. In Vitro Cell Dev. Biol. 31 (1995) 601-609
46. Redmond E.M., Cahill P.A., and Sitzmann J.V. Flow-mediated regulation of G-Protein expression in cocultured vascular smooth muscle and endothelial cells. Circulation (1997) 75-83
47. Redmond E.M., Cullen J.P., Cahill P.A., Sitzmann J.V., Stefansson S., Lawrence D.A., and Okada S. Endothelial cells inhibit flow-induced smooth muscle migration: Role of Plasminogen Activator Inhibitor-I. Circulation (2001) 597-603
48. Renkin E.M. Filtration, diffusion and molecular sieving through porous cellulose membranes. J. Gen. Physiol. 38 (1954) 225-243
49. Renkin E.M. Transport of large molecules across capillary walls. Physiol. 7 (1964) 13-28
50. Renkin E.M. Multiple pathways of capillary permeability. Circ. Res. 41 (1977) 735-743
51. Resnick R.B., Volavka J., Freedman A.M., and Thomas M. Studies on EN-1639A (naltrexone): a new narcotic antagonist. Am. J. Psychiatry 131 (1974) 646-650
52. Rothen-Weinhold A., Besseghir K., Vuaridel E., Sublet E., Oudry N., Kubel F., and Gurny R. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Eur. J. Pharm. Biopharm. 48 (1999) 113-121
53. Shah S.S., Cha Y., and Pitt C. Poly(glycolic acid-co-dl-lactic acid: diffusion or degradation controlled drug delivery?. J. Control. Rel. 18 (1992) 261-270
54. Sirisuth, N., Eddington, N.D., 2001. In vitro-in vivo correlation definitions and regulatory guidance. Int. J. Generic Drugs. Website: http://www.locumusa.com/pdf/members/ivivc-01.pdf, January 21, 2004.
55. Stevenson C.L., Theeuwes F., and Wright J.C. Osmotic implantable delivery systems. In: Wise D.L. (Ed). Handbook of Pharmaceutical Controlled Release Delivery (2000), Marcel Dekker Inc., New York 225-254
56. Stinchcomb A.L., Swaan P.W., Ekabo O., Harris K.K., Browe J., Hammel D.C., Cooperman T.A., and Pearsall M. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci. 91 (2002) 2571-2578
57. Therin M., Christel P., Li S.M., Garreau H., and Vert M. In vivo degradation of massive poly(α-hydroxy acids): validation of in vitro findings. Biomaterials 13 (1992) 594-600
58. Tzafriri A.R. Mathematical modeling of diffusion-mediated release from bulk degrading matrices. J. control. Rel. 63 (2000) 69-79
59. Verebey K., and Mule S.J. Naltrexone pharmacology, pharmacokinetics and metabolism: current status. Am. J. Drug Alcohol Abuse 2 (1975) 357-363
60. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., and O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 54 (1997) 737-742
61. Wagner J.G., and Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 53 (1964) 1392-1403
62. Weir N.A., Buchanan F.J., and Dickson G.R. Degradation of poly-l-lactide. Part 1. In vitro and in vivo physiological temperature degradation. Proc. Inst. Mech. Eng. Part H: J. Eng. Med. 218 (2004) 307-319
63. Zhao S., Pinholt E.M., Madsen J.E., and Donath K. Histological evaluation of different biodegradable and non-biodegradable membranes implanted subcutaneously in rats. J. Cranio-Maxillofacial Surgery 28 (2000) 116-122